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Deletion of Androgen Receptor in the Smooth Muscle
of the Seminal Vesicles Impairs Secretory Function
and Alters Its Responsiveness to Exogenous
Testosterone and Estradiol
Michelle Welsh, Lindsey Moffat, Laura Jack, Alan McNeilly, David Brownstein,
Philippa T. K. Saunders, Richard M. Sharpe, and Lee B. Smith
Medical Research Council Human Reproductive Sciences Unit (M.W., L.M., L.J., A.M., P.T.K.S., R.M.S.,
L.B.S.), Centre for Reproductive Biology, The Queen’s Medical Research Institute, and The Queen’s
Medical Research Institute (D.B.), Molecular Physiology, University of Edinburgh, Edinburgh EH16 4TJ,
United Kingdom
The seminal vesicles (SVs), like much of the male reproductive tract, depend on androgen-driven
stromal-epithelial interactions fornormal development, structure, and function. Theprimary func-
tion of the SVs is to synthesize proteins that contribute to the seminal plasma and this is androgen
dependent. However, the cell-specific role for androgen action in adult SVs remains unclear. This
study analyzed the SV inmice with targeted ablation of androgen receptors specifically in smooth
muscle cells (PTM-ARKO) to determine in vivo whether it is androgen action in a subset of the SV
stroma, the smooth muscle cells, that drives epithelial function and identity. These mice have
significantly smaller SVs in adulthood with less smooth muscle and reduced epithelial cell height.
Less epithelial cell proliferationwasobserved inadult PTM-ARKOSVs, comparedwith controls, and
production of seminal proteins was reduced, indicating global impairment of epithelial cell func-
tion in PTM-ARKO SVs. None of these changes could be explained by altered serum testosterone
or estradiol concentrations. We also demonstrate altered SV responsiveness to exogenous testos-
terone and estradiol in PTM-ARKO mice, indicating that smooth muscle androgen receptors may
limit the SV epithelial proliferative response to exogenous estrogens. These results therefore dem-
onstrate that the smooth muscle cells play a vital role in androgen-driven stromal-epithelial in-
teractions in the SV, determining epithelial cell structure and function as well as limiting the SV
epithelial proliferative response to exogenous estrogens. (Endocrinology 151: 3374–3385, 2010)
The seminal vesicles (SVs), like much of the male repro-ductive tract, depend on androgen action for normal
development and differentiation as well as for later struc-
tural and functional integrity (1–3). Testosterone (T) is
synthesized by the testes (4) and, along with its more po-
tent metabolite dihydrotestosterone (DHT), binds to the
androgen receptor (AR) tomodulate gene transcription in
target cells (5). Blocking androgen action impairs male
reproductive development such that XY males are born
with a female phenotype with intraabdominal testes, no
prostate, and no SVs (6–10). Androgen action in SVs is
thought to be regulated byDHT rather than T because SV
stromal cells express 5-reductase type 2, which converts
T to DHT, and 5-reductase knockout mice have smaller
SVs and prostates (11).
The primary function of the SVs is to synthesize pro-
teins that contribute to the seminal plasma. This is impor-
tant for the transport and nutrition of sperm as well as (in
rodents) the formation of a copulatory plug after ejacu-
lation; removal of the SVs frommice impairs fertility (12,
13). SVs have a highly convoluted pseudostratified colum-
nar epithelium with active protein secretory machinery.
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This epithelium is highly secretory producing fructose and
prostaglandins aswell as seminal fluid proteins such as SV
secretion proteins (SVS), metallothionein-1 (Mt-1), and
transglutiminase-4 (TGM4) (14–22). SV secretory func-
tion is androgen dependent (23), and castration after pu-
berty results in involution of the SVs due to a gross reduc-
tion in secretions as well as cytological degeneration and
apoptosis of the epithelium (24); these changes can be
reversed by exogenous T (25), suggesting that androgen
signaling is required for continued functional and struc-
tural homeostasis of SVs. Furthermore, it has been shown
that altering the androgen-estrogen balance can affect
adult male accessory sex organs because exogenous estro-
gens directly stimulate epithelial proliferation resulting in
aberrant histological changes and even prostatic squa-
mous metaplasia (26–32).
The SVs in adults are composed of epithelium sur-
rounded by stromal cells, including an inner contractile
layer of smoothmuscle. The cell-specific role for androgen
action in the SVs is poorly understood, withmuch ofwhat
we know being derived from prostate studies. Adult SVs
express AR in all cell types (namely the stromal, smooth
muscle, and epithelial cells) (33) and estrogen receptors
(ERs)- and - (34, 35). Normal male reproductive de-
velopment and function is believed to depend on recipro-
cal interactions between the stroma and epithelium; tissue
recombination studies, mostly on the prostate, have dem-
onstrated that the stromal compartment is the key site for
androgen action, determining the morphological and
functional fate of the overlying epithelium, and regulating
epithelial proliferation and apoptosis (36–40). Disrup-
tion of these hormone-driven interactions is implicated
in several pathologies including prostate carcinogenesis
(41). However, it is not known whether the epithelium
relies on interactionswith the entire stromal compartment
or whether signaling from a subset of the SV stromal com-
partment, the smooth muscle cells, is sufficient to deter-
mine epithelial identity and function.
Advances in transgenic technology have enabled cell-
specific gene ablation, providing new opportunities to in-
vestigate the cell-specific roles for androgen action. Tes-
ticular cell-specific AR knockout (ARKO)mice have been
successfully generated by several investigators (42–46),
including the generation of a testicular smoothmuscle cell
ARKO [termed PTM-ARKO (44)] using a smoothmuscle
promoter driven Cre recombinase mouse [namely myosin
heavy chain (47)]. This promoter also resulted in Cre ex-
pression in the smooth muscle cells of the SVs, therefore
providing a new opportunity to directly investigate
whether it is androgen action in a subset of the SV stroma,
the smoothmuscle cells, that drives epithelial function and
identity. As reported here, these mice have significantly
smaller SVs in adulthood with abnormal histology and
function, confirming similar observations in an indepen-
dent study in which a probasin-driven Cre inexplicably
resulted in Cre expression in the SV stroma cells (48). In
addition to this, we demonstrate altered responsiveness to
exogenousTandestradiol (E2) inourmice, indicating that
smooth muscle ARs might limit the SV epithelial prolif-
erative response to exogenous estrogens. Together these
results demonstrate a vital role for AR signaling via the
smooth muscle cells for normal SV structure and function
and reinforce the evidence that stromal-epithelial interac-
tions are important for adult sex accessory function.
Materials and Methods
Breeding of transgenic mice
Mice in which AR has been ablated from the smooth muscle
cells of the testis have already been generated (44), using male
mice heterozygous for Cre recombinase, and green fluorescent
protein (GFP), both under the control of a smooth muscle my-
osin heavy-chain promoter (MH) (47). These mice also ex-
pressed Cre recombinase in the smooth muscle cells of the SV.
The Cre-positive (ARflox positive) male offspring are termed
PTM-ARKO, whereas the Cre-negative ARflox-positive litter-
mates were used as controls. All mice were bred under standard
conditions of care and use under licensed approval from theU.K.
Home Office. Stud male MH mice and PTM-ARKO male off-
spring were genotyped for the presence of Cre using standard
PCR as previously described (44).
Recovery of reproductive tissues
Male mice were culled at postnatal d 12–100 and SVs were
recovered and weighed; these mice were also used to investigate
the phenotype in the testis (44) and prostate (Welsh M, Moffat
L,McNeilly A, BrownsteinD, Saunders PTK, SharpeRM, Smith
LB, manuscript in preparation). In adults, seminal secretions
were recovered, weighed, and snap frozen, and then the empty
gland was reweighed. To collect fetal SVs, dams were culled at
embryonic day (e)17.5, and reproductive tracts were recovered
frommale fetuses as previously described (44).Tissueswere snap
frozen for subsequent RNA analysis or fixed in Bouins for 6 h,
processed, and embedded in paraffinwax as previously reported
(10). Sections of SVs were stained with hematoxylin and eosin
using standard protocols and examined for histological
abnormalities.
Hormone implant study
Control (n 5) and PTM-ARKO (n 5) male mice (d 130–
150)were implantedwitha1-cmSILASTICbrand implant (Dow
Corning Corp., Midland, MI; inside diameter 1.47 mm, outside
diameter 1.95mm) containing T-E2 (Sigma-Aldrich, Poole, UK)
at a concentration ratio 100 mg T to 10mg E2, as used by Ricke
et al. (49). Implantswere left in situ for13wk,and thenmicewere
culled, blood was collected by cardiac puncture, and SVs were
recovered and weighed.
Hormone analysis
Immediately after culling, blood was collected from mice by
cardiac puncture and sera were assayed for testosterone and es-
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tradiol as previously published (50, 51). All samples from each
mouse were run in a single assay, and the within-assay coeffi-
cients of variation were all less than 10%.
Immunohistochemical analysis
In addition to PCR genotyping, mice were examined by im-
munohistochemistry for the presence of Cre and absence of AR
in SV smooth muscle cells, identified by immunoexpression of
-smooth muscle actin (SMA), using a previously published
method (44).
Single immunohistochemistry was also performed using pre-
viously published methods (10, 44). Adult SVs from PTM-
ARKO and control males were stained for: 1) GFP as a marker
for Cre expression (Abcam, Cambridge, UK; 1:100); 2) AR to
confirm its deletion (SantaCruzBiotechnology, Inc., SantaCruz,
CA; 1:200); 3) SMA to identify the smooth muscle cell layer
(Sigma-Aldrich; 1:4000); 4) pan-cytokeratin to identify the ep-
ithelial cells (Sigma-Aldrich; 1:1000); 4) ER to confirm the SVs
can respond to estradiol [Novocastra, Leica Microsystems
(U.K.) Ltd., Milton Keynes, UK; 1:20]; and 5) phosphohistone
H3 to identify mitotic cells (Upstate Biotechnology Inc., Lake
Placid, NY; 1:1000). Cellular sites of expression were deter-
mined and slides photographed using a Provis AX70microscope
(Olympus Optical, London, UK) fitted with a Canon DS6031
camera (Canon Europe, Amsterdam, The Netherlands). To en-
sure reproducibility of results, representative SVs from at least
three animals at each age were used, and sections from PTM-
ARKO and control littermates were processed in parallel on the
same slide on at least two occasions. Appropriate negative con-
trols were included to ensure that any staining observed was
specific. All antibodies used showed only minor nonspecific
staining.
Quantification of SV smooth muscle thickness and
epithelial cell height
Smoothmuscle thickness and epithelial cell heightwere quan-
tified in SV sections from adult PTM-ARKO and control
(TE2) mice stained for SMA and cytokeratin, respectively;
stereological analysis was undertaken on equivalent centrally
located sections for each animal; therefore, the measurements
should be at approximately equivalent points away from the SV
distal tips. Sections were analyzed using Image-Pro Plus 6.2 soft-
ware with a Stereology 5.0 plug-in (Media Cybernetics U.K.,
Berkshire, UK) with the 20 objective on a Leitz DBRB micro-
scope fitted with a Prior Pro-Scan automatic stage (Prior Scien-
tific InstrumentsLtd.,Cambridge,UK).Epithelial cell heightwas
measured in every 10th cell and smooth muscle thickness was
measured in the adjacent smooth muscle area.
Quantification of cell mitosis in SVs
SV sections from control and PTM-ARKO adult mice
(TE2)were immunostained for phosphohistoneH3 (Upstate
Biotechnology,Dundee,UK)asdetailedabove to identifymitotic
cells. Positive and negative cells were counted separately in the
epithelial compartment using Image-Pro Plus 6.2 software with
a Stereology 5.0 plug-in (Media Cybernetics U.K.) with the20
objective on a Leitz DBRB microscope fitted with a Prior Pro-
Scan automatic stage (Prior Scientific Instruments). The number
of positive cells in the epithelial compartment was then divided
by the total number of epithelial cells visible in section to calcu-
late the epithelial proliferation index.
Analysis of apoptosis in SVs
Apoptotic cells were identified in d 12 and d 100 SVs from
PTM-ARKO and control mice using terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate nick end label-
ing, as previously described (52). Very few apoptotic cells were
identified in knockout or control SVs at either age; therefore,
stereological quantification was deemed unnecessary.
Protein gels
SV secretions recovered from the glands at dissection were
homogenized in PBS before freezing at 80 C. Protein concen-
tration was quantified using a NanoDrop 1000 spectrophotom-
eter (Thermo Scientific, Swedesboro, NJ), and 40g was heated
to 70 C for 10 min and loaded onto a 4–12% (gradient) poly-
acrylamide gel. Gels were subjected to electrophoresis at 200 V
under reducing conditions.Gelswere stainedwith trypan blue to
reveal the protein fingerprint. Samples from at least three PTM-
ARKO and control males were run on at least three occasions.
RNA extraction and reverse transcription
RNAwas isolated and quantified from frozen SVs from PTM-
ARKOorcontrolmiceaspreviouslydescribed(44).Randomhexamer
primed cDNAwas prepared using the Applied Biosystems TaqMan
reverse transcription kit (Applied Biosystems, Foster City, CA).
Determination of deletion of AR exon 2
RT-PCR was performed as previously described on cDNA
synthesized from SVs from PTM-ARKO mice and control lit-
termates using primers for AR exons 1 and 3 to reveal bands of
765 and 613 bp relating to mice with a wild type (WT), and/or
excised exon 2 allele of AR, respectively. A weak central band
was also identified; this was confirmed to be an artifact.
Quantitative analysis of gene expression
Quantitative PCR was performed for the following genes,
using an ABI Prism 7500 sequence detection system (Applied
Biosystems) and the Roche universal probe library (Roche,Wel-
wyn, UK), according to the manufacturer’s instructions: SVS
protein 2 (GACAGTCAGCTGTGGTTGGA, GCCTTTCTGA-
CCAAGCATAAA), SVS3a (TCTCTGCTC CTCCTTCTGGA,
AAGTATCCTTTTGTTCCACCA), SVS3b (GCCTTTCTCT-
GCTCCTCCTT, TTCCCAATAAACATGAGTGGTG), SVS4
(AGCTGAACATCTGGACCAA, TGAAGACATC ATGGG-
CTCTGT), SVS5 (GCAAGATGAGTCCCACCAG, CGCCGA-
CTGAGAGAACCT), renin-1 (AAGAAAGTGTTCTCTGTC-
TACTACA, TCGCTACCTCCTAGCACCAC), transglutami-
nase-4 (TGM4) (CAGAGAGAGAGGTAGCAGGACCA,
TCTCTCCCATTCACAG CGTA), Mt-1 (CACCAGA-
TCTCGGAATGGAC, AGGAGCAGCAGCTCT TCTTG), cy-
clooxygenase (Cox)-1 (CTCTTCCAGGAGCTCACA, TC-
GATGTCACCGTACA GCTC). The expression of each gene
was related to 18S, an internal positive control.
Statistical analysis
Datawere analyzed usingGraphPad Prism version 5 (Graph-
Pad Software Inc., San Diego, CA) using a one-tailed unpaired t
test, one-way ANOVA, or two-way ANOVA, as appropriate,
followed by Bonferroni post hoc tests. Values are expressed as
mean  SEM. Normality was confirmed using a Kolmogoron-
Smirnov normality test.
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Results
Characterization of SVs in mice
with targeted deletion of AR from
smooth muscle cells
No reproductive phenotype was iden-
tified in adult MH Cre-positive, ARflox-
negative male mice, demonstrating that
Cre expression alone had no effect on
SVs (data not shown). All PTM-ARKO
males were hemizygous for X-linked
ARflox, whereas approximately 50% of
these males also carried the Cre trans-
gene [Fig. 1A, knockout (KO)]; the
ARflox-positive Cre-negative male litter-
mates were used as controls. To confirm
that Cre recombinase was functioning,
we assayed for the deletion of exon 2 of
theAR in PTM-ARKO SVs by RT-PCR.
Control SVs expressed only the full-
length (WT) band, whereas ARKO SVs
expressedonly the smallerKOband, con-
firming that exon 2 of the AR had been
deleted from all cells (Fig. 1B). SVs from
PTM-ARKO mice expressed both the
WT and KO band, as expected, demon-
strating thatAR had been deleted from a
proportion of SV cells (Fig. 1B). Immu-
nohistochemistry demonstrated that Cre
recombinasewas expressed in SVsmooth
muscle cells in PTM-ARKOmice at (Fig.
1C), whereas SVs from control mice
showed no specific Cre recombinase im-
munoexpression; Cre recombinase was
never expressed in any other SV cell type
in PTM-ARKOmice, including the outer
stromal layer. As expected,GFP,which is
coexpressed with Cre recombinase, was
also expressed only in the smoothmuscle
layer of the PTM-ARKO SVs (Fig. 1D,
arrow), whereas AR was absent in these
cells (Fig. 1E, arrow; arrowhead indicates
outer AR positive stromal layer).
Onset of Cre recombinase
expression in PTM-ARKO SVs
PTM-ARKO SVs from e17.5 em-
bryos were assayed for the deletion of
exon 2 of theAR byRT-PCR, as used in
Fig. 1B. SVs from control mice ex-
pressed only the full-length (WT) band,
whereas SVs from PTM-ARKO mice
expressed both theWT and smaller KO
FIG. 1. A, Characterization of Cre recombinase expression in adult PTM-ARKO seminal
vesicles. Approximately 50% of male PTM-ARKOs were Cre positive, identified by the
presence of a band at 100 bp. Control littermates were negative for Cre but were
positive for the internal control gene. B, Deletion of AR in the adult SV was determined
using RT-PCR spanning exon 2. Only the larger 765-bp WT band was seen in control SVs,
whereas the smaller 613-bp KO band was seen in ARKO testes. Both bands were
identified in PTM-ARKO SVs, showing deletion of AR in a proportion of cells. C,
Immunohistochemistry for Cre recombinase (green) and SMA (blue) showed that Cre
recombinase was expressed selectively (arrow) in the smooth muscle cells of the SVs but
not in any other SV cell types or smooth muscle cells in control SVs (*). Note that the
smooth muscle layer appears narrower in the PTM-ARKO than controls. D, GFP
[expression of which is also driven by the MH promoter in this mouse (47)] was expressed
in the smooth muscle cells in PTM-ARKO SVs at d 100 (*) but not in the outer stromal
cell layer (arrow); GFP was not detected in any cells in control SVs. Scale bars, 50 m.
E, In contrast, AR was expressed in the smooth muscle cells of control SV (arrowhead)
but not PTM-ARKO SV smooth muscle cells (*); AR continued to be expressed in the
epithelial and outer stromal cells (arrow) in the PTM-ARKO SV. Scale bars, 25 m.
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band (data not shown). Therefore, AR is deleted from
smooth muscle cells around the age at which AR is nor-
mally first expressed (data not shown).
SV gross morphology in PTM-ARKO mice
Serum T [control, 3.5  0.94 ng/ml1, n  15; KO,
4.87  1.2 ng/ml1; (44)] and E2 (control, 5.2  0.8
pg/ml1, n  3; KO, 5.7  1.0 pg/ml1, n  5) concen-
trations were not significantly different in adult PTM-
ARKO males, compared with age-matched control lit-
termates. Body weight was not significantly different
between PTM-ARKO and control males at any age (data
not shown). The reproductive tract formed normally in
PTM-ARKOmales; however, SVweights were reduced at
d 35, 50, and 100, comparedwith controls, but not at d 21
(Fig. 2A); prostate weight was also reduced in PTM-
ARKO males (Welsh M, Moffat L, McNeilly A, Brown-
steinD, Saunders PTK, SharpeRM, Smith LB,manuscript
in preparation). These changes in SV weight could not be
explained by correcting for body weight (data not
shown). Theweight of the emptied SVswas significantly
reduced in PTM-ARKOs, compared with controls at d
100, as was the volume of SV secretions (Fig. 2B). The
ratio of SV secretions was: emptied SV was also signif-
icantly reduced in PTM-ARKO mice, compared with
controls (Fig. 2B), implying that the SVs from KO mice
make disproportionately less secretions for their size.
Postnatal SV histology
The SVs fromboth PTM-ARKOand controlmicewere
composed of glands lined by epithelium surrounded by an
inner smooth muscle layer and an outer stroma cell layer.
The lumens of both the PTM-ARKOand control SVswere
filled with a dense eosinophilic substance (Fig. 3A, aster-
isk). Tall secretory columnar epithelium was observed in
the control SV, with typical folding of the mucosa (Fig.
3A), whereas the epithelium in the PTM-ARKO SVs was
more cuboidal (Fig. 3B), as confirmed quantitatively (Fig.
3C). There was also an apparent increase in epithelial
branching/folding in the PTM-ARKO, compared with
controls (Fig. 3A, arrowhead). In addition to epithelial
changes, there was a reduction in the depth of the
smooth muscle layer in the PTM-ARKO SV, compared
with the controls (Fig. 3D); this was confirmed quan-
titatively (Fig. 3E). Interestingly, the stromal compart-
ment is mostly composed of smooth muscle cells in the
mouse SVs, with only a thin SMA-negative outer layer
(Fig. 3D, arrowhead).
Proliferation and apoptosis in PTM-ARKO SVs
There was no significant difference in the number of
mitotic cells in PTM-ARKO SVs at d 12, compared with
controls; however, there was a significant increase in ep-
ithelial cell mitosis at d 100 in PTM-ARKOs compared
with controls (Fig. 4). Very few apoptotic cells were iden-
FIG. 2. Gross morphology of PTM-ARKO seminal vesicles. A, Quantification of SV weight in PTM-ARKO mice at d 21–100 showing that there is a
significant reduction at d 35 onward but not at d 21. B, Quantification of empty SV minus secretion and SV secretion weight as well as secretion
weight relative to SV weight in PTM-ARKO mice at d 100. Values are means  SEM (n  6–14 mice). *, P  0.05, **, P  0.01, ***, P  0.001,
compared with age-matched controls.
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tified in either KO or control SVs at d 12 or 100 (data not
shown).
Secretion of SV plasma proteins in PTM-ARKOs
Four main proteins were identified when SV secretions
from PTM-ARKO and control mice were subjected to
electrophoresis; there was no obvious difference in the
protein fingerprint observed between PTM-ARKO and
controls (Fig. 5A).QuantitativeRT-PCR for genes known
to be involved in SV function revealed no significant dif-
ference in expression of SVS2/3a/3b/5, renin-1, TGM-4,
orMt-1, but there was a significant increase in expression
of Cox-1mRNA, compared with controls (normalized to
18S expression; Fig. 5B).
Expression of ERs in SVs from PTM-ARKO adult
mice
Immunohistochemistry demonstrated that ER is ex-
pressed in stromal and occasional epithelial cells in both
control and PTM-ARKO adult SVs (Fig. 6), therefore
demonstrating that KO SVs are capable of responding to
estrogens.
FIG. 3. Histological analysis of PTM-ARKO seminal vesicles. A, Hematoxylin and eosin staining of d 100 PTM-ARKO and control SVs
composed of epithelia surrounded by a stromal compartment (arrow); this epithelium appeared more folded in PTM-ARKO SVs than control
(arrowhead). Note the dense eosinophilic seminal secretions in the lumen of both the PTM-ARKO and control SV (*). Scale bars, 400 and 50
m, respectively. B, Immunohistochemistry for cytokeratin (brown), highlighting the epithelial cells in d 100 PTM-ARKO and control SVs. C, Note
that epithelial cell height is significantly reduced in PTM-ARKOs at d 100 but not d 12, compared with age-matched controls. Scale bars, 50 m.
D, SMA immunostaining (brown) identifying the smooth muscle cell layer (arrow) directly surrounding the epithelium in d 100 PTM-ARKO and
control SVs; note the presence of an outer SMA-negative layer (arrowhead). E, The smooth muscle layer is narrower in the PTM-ARKO than the
control, as confirmed quantitatively. Values are means  SEM (n  3 mice). *, P  0.05, **, P  0.01, compared with age-matched controls. Scale
bars, 50 m.
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Gross morphology of SVs from adult PTM-ARKO
mice treated with exogenous T and E2
Treatment with estrogens is reported to stimulate epithe-
lial proliferation in SVs and prostates (26, 27, 32) and in-
duces prostate squamousmetaplasia (31). Exogenous estro-
gens result in suppression of gonadotropins and so testicular
T production. We therefore treated control and PTM-
ARKOadultmalemicewithexogenousTandE2(TE2)for
13 wk to assess their response to estrogens without causing
SV involution due to reduced serum T. This treatment re-
sultedinnormalserumTconcentrations(3.5ng/ml10.17
in controls and4ng/ml10.47 in PTM-ARKOs); thiswas
not significantly different from untreated mice (44). Serum
E2concentrationswere2200pg/ml157 inTE2-treated
controls and 2404 pg/ml1 57 in TE2-treated KOs; this
is an approximately 400-fold increase comparedwith serum
estradiol concentrations in control andKOmalesnot treated
with TE2. SVs recovered from adult control mice exposed
to TE2 were significantly larger than those from controls
not treated with TE2; conversely, there was no significant
change in SV weight in PTM-ARKO mice after treatment
with TE2 (Fig. 7A).
Histology of PTM-ARKO SVs exposed to T and E2
Upon gross histological inspection, the TE2-treated
control and PTM-ARKO SV contained eosinophilic se-
cretions in the lumen and showed signs of hyperplasia and
hypertrophy (Fig. 7B), as seen from the densely packed
nuclei in the stroma and epithelium. This hyperplasia and
hypertrophy was not obvious in untreated control or
PTM-ARKO SVs (Fig. 3A) and was more severe in the
TE2-treatedPTM-ARKOSVthan inTE2-treated con-
trol SVs (confirmed by an expert pathologist). This hy-
perplasia resulted in desquamation of epithelial cells in
some KO SVs due to overcrowding of epithelial cells and
sloughing off (Fig. 7B, right panel). There was also an
apparent increase in epithelial branching in both the con-
trol and PTM-ARKO SVs exposed to TE2 (Fig. 7B),
compared with untreated control and PTM-ARKO SVs,
respectively (Fig. 3A). Epithelial cell height did not signifi-
cantly change in SVs from PTM-ARKO and control mice
treated with TE2, compared with untreated PTM-ARKO
and control SVs, respectively (Fig. 8A). Epithelial cell height
therefore remained significantly smaller in TE2-treated
PTM-ARKOSVs than controls (Fig. 8A).
However, the depth of the SV smooth
muscle cell layer significantly increased in
TE2-treated mice, compared with un-
treated mice (Fig. 8B); however, the
smooth muscle layer remained signifi-
cantly smaller in TE2-treated PTM-
ARKOSVs, comparedwith TE2-treated
controls (Fig. 8B). Quantification of the
percentage of epithelial cells undergoing
mitosis in adult PTM-ARKOand control
SVs treated with TE2 revealed signifi-
cantly more epithelial cell mitosis in
PTM-ARKO SVs than in controls, both
with and without TE2 exposure (Fig.
8C). There was a significant increase in
epithelial mitosis in control SVs treated
with TE2, compared with untreated
controls, but treatment with TE2 did
not significantly alter epithelial cell mito-
sis in PTM-ARKO SVs (Fig. 8C).
FIG. 5. SV secretion production in PTM-ARKO mice. A, Seminal secretion protein expression
in PTM-ARKO and control adult mice. There are four major proteins observed in the seminal
secretions in both KO and control mice with no obvious differences in expression. B, Relative
gene expression in SVs from d 100 PTM-ARKO and control mice. Note that the only gene
that significantly changes is Cox-1, which is significantly increased in PTM-ARKO mice,
compared with controls. Values are means  SEM (n  3 mice). *, P  0.05, compared with
control littermates.
FIG. 4. Cell mitosis in PTM-ARKO seminal vesicles. Quantification of
epithelial cell mitotic index in d 12 and 100 PTM-ARKO and control
SVs. Values are means  SEM (n  3 mice). *, P  0.05, compared
with age-matched control littermates.
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Discussion
Androgens and stromal-epithelial interactions are pivotal in
the development and function of the male reproductive sys-
tem (1, 2); disruption of these can result in pathologies later
in life. The cell-specific role for androgenaction in adult SVs,
however, remains unclear. The aim of this study was to in-
vestigate the impact of ablating androgen action specifically
from SV smooth muscle cells on SV development and adult
function. Our analysis revealed that the smoothmuscle cells
play an important role in androgen-
driven stromal-epithelial interactions in
the SV, determining epithelial cell struc-
ture and function as well as limiting the
SV epithelial proliferative response to ex-
ogenous estrogens.
Cross-breeding ARflox female mice
with smooth muscle myesin heavy
chain-Cre male mice ablated AR from
the smoothmuscle cells in theSVs fromas
early as e17.5. In contrast to ARKOmice
(43), PTM-ARKOmales showed normal
external sexual development and anogenital distance (44)
and SVs formed normally, but there was a significant reduc-
tion in SV weight after puberty. Serum T and estrogen con-
centrations were normal in PTM-ARKO mice, confirming
that the reduction in adult SV sizemust be due to ablation of
AR from the SV smoothmuscle. Furthermore, expression of
Cre alone, without ARflox expression, did not result in any
changes in SVweight or histology.Thephenotypeof the SVs
in PTM-ARKOs is similar to that recently reported by Si-
manainen et al. (48), who deleted AR
fromtheSVstromal smoothmuscleusing
a probasin-drivenCre (named PEARKO
mice); comparison of these two inde-
pendentmousemodels is summarized in
Supplemental Table 1 published on The
Endocrine Society’s JournalsOnlineweb
siteathttp://endo.endojournals.org.The
probasin-driven Cre is expressed from
postnatal wk 5 in PEARKOmice, but it
is unclear whether Cre expression is re-
stricted solely to the smooth muscle
layer or is expressed in all stromal cells
in the SV; this uncertainty was not clar-
ified by Jin et al. (53), who generated
this probasin Cre mouse. Our PTM-
ARKO mouse study therefore offers
new evidence that AR signaling specif-
ically via the smooth muscle cells alone
is important for adult SV size and
function.
SVs formed normally in the PTM-
ARKO mice, and there was no obvious
change in SV weight before d 35, even
though AR ablation could be identified
at e17.5. Because AR expression in the
mesenchyme of the developing sex ac-
cessory organs is critical for normal de-
velopment and epithelial identity (39,
54), ablation of AR from the fetal
smooth muscle might have been ex-
FIG. 6. ER expression in adult PTM-ARKO SVs. Immunoexpression of ER (green) in adult
PTM-ARKO and control SVs; nuclei are counterstained red.
FIG. 7. Gross morphology and histology of adult PTM-ARKO mice exposed to exogenous T and
E2. A, Quantification of SV weight in adult PTM-ARKO mice exposed to T and E2 for 13 wk. Note
the increase in SV weight in control but not KO mice after exposure to TE2. B, Hematoxylin and
eosin staining of adult PTM-ARKO and control SVs exposed to TE2, with dense esinophilic
seminal secretion in the lumen of both the PTM-ARKO and control SV (*). Note the densely
packed cell nuclei in both the stroma and epithelia in control and PTM-ARKO SVs exposed to
TE2; this is more pronounced in KOs than controls, with desquamation of epithelial cells
obvious in some KO SVs (arrow). Values are means SEM (n 3 mice). ***, P 0.001,
compared with control littermates; **, P 0.01, compared with untreated control mice.
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pected to affect SV formation. However, Cre expression,
and hence AR deletion, will not be induced until the
smooth muscle layer has actually differentiated; this hap-
pens during late fetal life, after the SV have been prepro-
grammed to form (9); therefore, onset ofCre expression in
the PTM-ARKO is likely to be too late
to affect SV formation. This PTM-
ARKO model therefore offers a unique
opportunity to interrogate androgen ac-
tion specifically in the smooth muscle
layerof thestromawithoutpreventingSV
formation in fetal life. However, we can-
not rule out a prepubertal role forAR sig-
naling via the smooth muscle cells of the
SVbecause, even though therewasnosig-
nificant decrease in SV weight before d
35, a reduction in thedepthof the smooth
muscle layer could be identified at d 12.
Epithelial cells are normally pseudo-
stratified and columnar in adult SVs,
with epithelial cell height reported to be
androgen dependent (55), possibly act-
ing as amore sensitivemarker of andro-
gen action than gross changes in gland
weight (55). Epithelial cell height was
significantly reduced in adult PTM-
ARKO SVs, demonstrating that the
smooth muscle cells are important to
specifying the identity of the overlying
epithelium during development and in
adulthood. This dedifferentiation of the
SV epithelium in PTM-ARKOsmay ex-
plain the reduction in epithelial cell
function reflected in reduced SV secre-
tion volume. Interestingly, there was a
significant increase in SV epithelial cell
height from d 12 to d 100 in controls,
but this increase was less apparent in
PTM-ARKOs, demonstrating that the
SV epithelium differentiates as it ma-
tures and that this is dependent, at least
in part, on AR signaling via the smooth
muscle cells. The depth of the smooth
muscle layer was also reduced in PTM-
ARKO SVs, compared with controls.
Unlike changes to the epithelium, the re-
duced depth of the smooth muscle layer
was evident in PTM-ARKOs at both d
12 and 100. This agrees with the phe-
notype previously reported in PEARKO
mice (Supplemental Table 1) (48) and
suggests that AR signaling within the
smoothmuscle layer itself determines its
depthand that this in turnmayplay a role in SVweight and
epithelial function in adulthood.
The reduction in adult SV weight in PTM-ARKOs was
due to a reduction in the weight of the SV tissue plus a
FIG. 8. Quantification of histological changes in adult PTM-ARKO seminal vesicles after
exposure to T and E2. A, Epithelial cell height (immunostained for cytokeratin, brown) is
significantly reduced in PTM-ARKO SVs treated with TE2, compared with TE2-treated
controls (as reported in untreated mice). Exposure to TE2 does not result in any change in
epithelial cell height, compared with untreated PTM-ARKOs and controls, respectively. B, The
depth of the smooth muscle cell layer (immunostained for SMA, brown, *) is significantly
smaller in PTM-ARKO SVs treated with TE2, compared with treated controls. Note that
exposure to TE2 results in a significant increase in this smooth muscle layer in PTM-ARKO
and control SVs, compared with untreated PTM-ARKOs and controls, respectively. C,
Quantification of epithelial cell mitosis revealed a significant increase in epithelial mitosis in
control SVs treated with TE2, compared with untreated controls. Note that there is
significantly more epithelial cell mitosis in PTM-ARKO SVs than controls but that treatment
with TE2 does not significantly alter epithelial cell mitosis in PTM-ARKO mice. Values are
means  SEM (n  3 mice). *, P  0.05, compared with control littermates or untreated
mice; **, P  0.01, compared with control littermates.
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reduction in SV secretions, a function of the epithelial
cells. The reduction in SV secretionswas disproportionate
to the reduction in SV tissue weight, suggesting that ab-
lation of AR specifically from the smooth muscle impairs,
but does not completely abolish, normal adult SV secre-
tory function. This is supported by the detection of a sim-
ilar protein fingerprint for SV secretions from PTM-
ARKO adult males to that in control males. PTM-ARKO
SV epithelial cells are able tomake themajor proteins that
contribute to seminal plasma, suggesting a global impact
on epithelial cell function without selectively affecting
production of specific proteins. Thismay result in smaller,
more fragile plugs as reported in the PEARKO (48), thus
explaining why PTM-ARKO mice rarely (one of 18 mat-
ings) produced copulatory plugs, unlike their control lit-
termates (produced plugs in 17 of 24 matings). This im-
paired seminal plasmaproductionmaybe adirect result of
AR ablation from the SV smooth muscle or indirectly due
to the thinner layer of smooth muscle in these mice. Our
findings therefore confirm the important role for andro-
gen-driven sex accessory organ function in fertility and
demonstrate that the presence of a functioning androgen-
responsive smoothmuscle compartment is critical for nor-
mal SV epithelial function.
Interestingly, relative expression of some genes impor-
tant in seminal fluid production (namely SVS2/3/5, Mt-1,
andTGM-4) was not significantly altered in PTM-ARKO
SVs, consistent with the view that ablating AR from the
smooth muscle has a global impact on epithelial function,
rather than impairing production of specific proteins.
However, relative expression of Cox-1 mRNA was sig-
nificantly increased in SVs from PTM-ARKO adults com-
pared with controls. Cox-1 is constitutively expressed in
mouse SV epithelium to produce prostaglandins (16),
which have been suggested to be involved in sperm mo-
tility and capacitation (56) and relaxation of the smooth
muscle of the uterus (57). It is not immediately clear why
expression ofCox-1 increases in PTM-ARKOmice, but it
is indicativeof alteredepithelial function in thesemice; this
may be a direct result of the absence of smoothmuscle AR
or an indirect consequence of the reduced smooth muscle
layer in these mice.
Growth and development of an organ depends on not
just differentiation of the tissue but also a balance of cell
proliferation and apoptosis. Apoptosiswas not obvious in
the SV from either control or PTM-ARKOmice at d 12 or
100, but epithelial cell proliferation was significantly in-
creased in adult PTM-ARKOs, resulting in obvious hy-
perplasia. Epithelial cell proliferation is dependent on an-
drogen action in SVs and prostates (55), and it has been
demonstrated using prostatic tissue recombination exper-
iments that stromal, not epithelial, AR is important in
regulating epithelial cell proliferation in the prostate (39,
54, 58). However, what controls epithelial cell prolifera-
tion in adult SVs is less clear. Our study demonstrates that
ablating AR from smoothmuscle cells increased epithelial
cell proliferation, implying that androgen signaling via the
smooth muscle normally suppresses epithelial cell prolif-
eration in adulthood to maintain tissue homeostasis; this
may be a direct effect on the epithelial cells themselves or
an indirect effect due to changes in the proportion of
smooth muscle in the SVs, i.e. as reported in the prostate
(reviewed in Ref. 59). Interestingly, epithelial cell-specific
ablation of AR in the prostate also results in increased
proliferation (60, 61). These results could imply that ep-
ithelial cell proliferation is differentially regulated in the
prostate and SVs or that it is a balance of androgen action
via either epithelial and/or smooth muscle cells that is im-
portant and impairing either is detrimental to normal tis-
sue homeostasis.
Adult prostates and SVs are able to directly respond to
both androgens and estrogens as they express both AR
(33) and ER and -. Previous studies demonstrated that
altering theandrogen-estrogenbalance canaffect theadult
male accessory sex organs (26–32). For example, exoge-
nous estrogens directly stimulate epithelial cell prolifera-
tion in the SVs and prostate (26, 27, 32, 62) as well as
inducing prostate squamous metaplasia via ER (31). We
demonstrated that PTM-ARKO SVs continued to express
ER and therefore should still be capable of responding to
estradiol treatment; therefore, we investigated whether a
lack of smooth muscle AR affected PTM-ARKO SV re-
sponse to exogenous E2. Because E2 exposure results in
suppression of gonadotropins and thus of testicular Tpro-
duction, which would result in SV involution (63), we
treated control and PTM-ARKO adult male mice with
exogenous T and E2 (TE2) for 13 wk to assess their
response to estrogenswithout causing SV involution. This
treatment regimen resulted in normal serum T levels in
PTM-ARKOs and controls, but serum E2 concentrations
were elevated 400-fold compared with nontreated PTM-
ARKO and controls; therefore, any effects seen after this
treatment are likely to be direct effects of estrogens. Ex-
posure to TE2 resulted in a significant increase in SV
weight in controls but not PTM-ARKOs but had no effect
on epithelial cell height, suggesting that estrogens do not
directly affect epithelial cell differentiation. On the other
hand, this treatment resulted in a significant increase in the
depth of the smooth muscle layer in both control and
PTM-ARKO SVs. As a similar increase was seen in both
controls and PTM-ARKOs, which have no AR in the
smooth muscle cells to respond to the T, this increase is
likely to be mediated by the E2. Exposure to TE2 also
increased epithelial cell proliferation in both controls and
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PTM-ARKO SVs, resulting in hyperplasia and hypertro-
phy of the epithelium and stroma. This hyperplasia was
more pronounced in the PTM-ARKO than in control and
resulted in overcrowding of the epithelium and thus des-
quamation in PTM-ARKOs; the latter change was not
seen in any of the SVs fromcontrols examined. Therewere
no obvious signs of inflammation in either controls or
PTM-ARKO SVs treated with TE2. Our results demon-
strate that smoothmuscle AR signaling suppresses epithe-
lial cell proliferation in adult SVs and that, in its absence,
estrogens can cause uncontrolled proliferation and hyper-
plasia in the SV.
In conclusion, we have successfully generated a PTM-
ARKO mouse SV model that demonstrates the essential
role forAR signaling via smoothmuscle cells in normal SV
function and male fertility. This mouse model provides a
unique tool for identifying the underlying molecular
mechanisms of androgen action in the SVs without pre-
venting SV formation. Further investigations with these
mice could provide new insight for the development of new
male contraceptives and treatments for male infertility.
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